Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02574078 · ClinicalTrials.gov registry record · Phase 1
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 341
- Enrollment target
NCT02574078: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT02574078 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 341 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (468% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02574078, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 341 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
Primary Outcome
Progression-free survival (PFS) is defined as the time from randomization to the date of the first documented tumor progression, as determined by investigators (per RECIST v1.1), or death due to any cause, whichever occurs first.
Interventions
- DRUG Bevacizumab
- DRUG Pemetrexed
- DRUG Nivolumab
- DRUG nab-Paclitaxel
- OTHER Best Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2015-11-23 |
| Est. Completion | 2020-04-15 |
| Phase | Phase 1 |
What the finished NCT02574078 record still lists
NCT02574078 is an interventional study that assigns participants to a tested intervention. The registered 341 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (468% higher).
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT02574078 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02574078 about?
NCT02574078 is a clinical study titled "A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
What is the current status of trial NCT02574078?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 341 participants. The study started on 2015-11-23. Estimated completion is 2020-04-15.
What interventions are being tested in trial NCT02574078?
The interventions under investigation include: Bevacizumab (DRUG), Pemetrexed (DRUG), Nivolumab (DRUG), nab-Paclitaxel (DRUG), Best Supportive Care (OTHER).
Who is sponsoring clinical trial NCT02574078?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02574078's enrollment target sits among peer trials
341 104th of 2000 higher than 1,897 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI